# Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

> **NCT03207243** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 165 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK3772847
- **DRUG:** Placebo
- **DRUG:** Fluticasone propionate/salmeterol
- **DRUG:** Fluticasone propionate

## Key facts

- **NCT ID:** NCT03207243
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-14
- **Primary completion:** 2019-02-15
- **Final completion:** 2019-05-15
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207243, "Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03207243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*